Clinical characteristics of KRAS mutations in NSCLC and their impact on outcomes to first-line chemotherapy

被引：0
|
作者：
Butaney, Mohit
Porter, Jennifer
Lindeman, Neal Ian
Janne, Pasi A.
Rabin, Michael S.
Marcoux, J. Paul
Johnson, Bruce E.
Jackman, David Michael
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7588
引用
收藏
页数：1
相关论文
共 50 条
  • [31] First-Line Atezolizumab Plus Chemotherapy in Chemotherapy-Naive Patients with Advanced NSCLC: A Phase III Clinical Program
    Jotte, Robert M.
    Socinski, Mark A.
    Reck, Martin
    Papadimitrakopoulou, Vassiliki
    West, Howard J.
    Mok, Tony
    Sandler, Alan
    Mocci, Simonetta
    Coleman, Shelley
    Asakawa, Takashi
    Cappuzzo, Federico
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (11) : S302 - S303
  • [32] First-Line Atezolizumab plus Chemotherapy in Chemotherapy-Naive Patients with Advanced NSCLC: A Phase III Clinical Program
    Cappuzzo, Frederico
    Reck, Martin
    Papadimitrakopoulou, Vassiliki
    Jotte, Robert
    West, Howard
    Mok, Tony
    Sandler, Alan
    Mocci, Simonetta
    Coleman, Shelley
    Asakawa, Takashi
    Socinski, Mark
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1296 - S1297
  • [33] Impact of Baseline Clinical Biomarkers on Treatment Outcomes in Patients With Advanced NSCLC Receiving First-line Pembrolizumab-Based Therapy
    Joshi, Ishani
    Peravali, Monica
    Geng, Xue
    Rao, Suman
    Chen, Kevin Y.
    Veytsman, Irina
    Giaccone, Giuseppe
    Liu, Stephen, V
    Kim, Chul
    CLINICAL LUNG CANCER, 2022, 23 (05) : 438 - 445
  • [34] Prognostic Impact of KRAS Mutational Status in Patients with Advanced Lung Adenocarcinoma Receiving First-Line Cytotoxic Chemotherapy
    Desai, Arpita
    He, Xiangyun
    Gandhi, Shipra
    Wang, Chong
    Meagher, Alison
    Dy, Grace K.
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S421 - S421
  • [35] Outcomes in NSCLC Patients with EGFR Co-Mutations Receiving Aumolertinib as First-Line Treatment: the Updated Results
    Fang, S.
    Xu, T.
    Liu, N.
    Wang, X. Y.
    Cheng, W. W.
    Fang, H. H.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S650 - S650
  • [36] KRAS Mutations in Colorectal Cancer: Relationship With Clinicopathological Characteristics and Impact on Clinical Outcomes in Saudi Arabia
    Alghamdi, Mohammed
    Alabdullatif, Nujud
    Al-Rashoud, Ajeed
    Alotaibi, Joud
    Alhussaini, Nouf
    Elsirawani, Sedra
    Somily, Haneen
    Alkhudair, Norah
    AlOtaiby, Maram
    Ahamed, Shaik S.
    Abd El-Aziz, Nashwa
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (03)
  • [37] First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC
    Zhou, Caicun
    Solomon, Benjamin
    Loong, Herbert H.
    Park, Keunchil
    Perol, Maurice
    Arriola, Edurne
    Novello, Silvia
    Han, Baohui
    Zhou, Jianying
    Ardizzoni, Andrea
    Mak, M. Perez
    Santini, Fernando C.
    Elamin, Yasir Y.
    Drilon, Alexander
    Wolf, Juergen
    Payakachat, Nalin
    Uh, Minji K.
    Rajakumar, Deborah
    Han, Hongmei
    Puri, Tarun
    Soldatenkova, Victoria
    Lin, A. Bence
    Lin, Boris K.
    Goto, Koichi
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 389 (20): : 1839 - 1850
  • [38] Intercalated chemotherapy and erlotinib: a viable first-line option for patients with advanced NSCLC?
    Zheng, Yulong
    Xu, Nong
    Zhou, Jianying
    LANCET ONCOLOGY, 2013, 14 (11): : E438 - E438
  • [39] Influence of baseline inflammatory markers on the response to first-line chemotherapy in advanced NSCLC
    MacDonald, N.
    Kasymjanova, G.
    Agulnik, J. S.
    Pepe, C.
    Kreisman, H.
    Cohen, V.
    Sharma, R.
    Gagnon, B.
    Small, D.
    EJC SUPPLEMENTS, 2007, 5 (04): : 385 - 385
  • [40] Cimavax-EGF in Combination with First-Line Chemotherapy in III Stage NSCLC
    Neninger, E.
    Caceres, H.
    Camacho, K.
    Hernandez, M.
    Santiesteban, E.
    Del Castillo, C.
    Menendez, Y.
    Gonzalez, B.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S676 - S677
12345